Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03897621 · ClinicalTrials.gov registry record · NA

The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery

A NA study of Total Hip Arthroplasty and Tranexamic Acid, sponsored by Thomas Jefferson University.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT03897621: Completed NA study of Total Hip Arthroplasty and Tranexamic Acid, sponsored by Thomas Jefferson University.

NCT03897621 is a NA study of Total Hip Arthroplasty and Tranexamic Acid that has completed, run by Thomas Jefferson University. The registered enrollment target is 50 participants, below the 141-participant average among 12 other Total Hip Arthroplasty trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03897621, a NA study of Total Hip Arthroplasty and Tranexamic Acid, has completed, sponsored by Thomas Jefferson University.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Total hip arthroplasty (THA) is associated with blood loss ranging from 300 to 2000 mL. Tranexamic acid (TXA) is frequently administered prophylactically during this procedure to reduce blood loss by inhibiting fibrinolysis or by stopping naturally occurring clot resolution. TXA is employed currently based on a surgeon's preference. The objective of this study is to quantitate the degree of fibrinolysis using rotational thromboelastometry (ROTEM) and investigate the role of TXA prophylaxis on blood loss in patients undergoing THA in a double-blind fashion. Our hypothesis is that fibrinolysis is minimal at most and TXA prophylaxis is not necessary during THA. All patients, whether they receive TXA or normal saline, will not be at risk, as at this time no data exists to determine which approach is safer or more effective. This is the first study to compare TXA vs. placebo in a double-blinded, randomized controlled trial.

Primary Outcome

Fibrinolysis based on ROTEM parameter, defined as ML (maxium lysis) \>15%

Interventions

  • DRUG Placebo
  • DRUG Tranexamic Acid

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2019-05-20
Est. Completion 2022-12-20
Phase NA
Thomas Jefferson University

292 total trials

What the finished NCT03897621 record still lists

NCT03897621 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 141-participant average among 12 other Total Hip Arthroplasty trials with a reported enrollment target (65% lower).

The record links to 5 conditions, with Total Hip Arthroplasty appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03897621 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03897621 about?

NCT03897621 is a clinical study titled "The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery". Total hip arthroplasty (THA) is associated with blood loss ranging from 300 to 2000 mL. Tranexamic acid (TXA) is frequently administered prophylactically during this procedure to reduce blood loss by inhibiting fibrinolysis or by stopping naturally occurring clot resolution. TXA is employed currentl...

What is the current status of trial NCT03897621?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2019-05-20. Estimated completion is 2022-12-20.

What conditions does trial NCT03897621 study?

This clinical trial studies the following conditions: Total Hip Arthroplasty, Tranexamic Acid, Rotational Thromboelastometry, Fibrinolysis; Hemorrhage, Coagulation; Intravascular.

What interventions are being tested in trial NCT03897621?

The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (DRUG).

Who is sponsoring clinical trial NCT03897621?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03897621 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Total Hip Arthroplasty

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03897621's enrollment target sits among peer trials

50 12th of 12 higher than 1 of 12 other Total Hip Arthroplasty trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Total Hip Arthroplasty trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03897621, the US trial registry maintained by the National Library of Medicine. NCT03897621 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.